A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...

The scrutiny follows allegations of data manipulation and misleading claims about the drug's effectiveness, leading the Securities and Exchange Commission to charge the company, which resulted in a ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

74-year-old Norman Colpitts is living with the early stages of Alzheimer's disease, but he's taking lecanemab. That's one of two FDA-approved drugs to ... to it. I'd get an infusion and come ...

SciSparc receives FDA approval for a Phase ... the company is also exploring its potential for Alzheimer's disease and agitation. “We believe our innovative drug candidate SCI-110 has the ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...